Organogenesis (NASDAQ:ORGO) Announces Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Key Points

• Organogenesis missed quarterly estimates: EPS was a loss of $0.23 versus the expected loss of $0.18, while revenue of $45.46 million fell short of the $52.10 million consensus.
• Third-quarter net product revenue declined 70% year over year, and the company lowered its 2026 revenue outlook to $179 million–$200 million. Management cited a slower-than-expected market recovery despite sequential sales growth and market-share gains.
• The company recorded a $29.6 million GAAP net loss, with cash and restricted cash falling to $26.9 million. FDA review of Amnuvx is also facing a longer timeline after the agency requested facility remediation and additional clinical information.

Organogenesis (NASDAQ:ORGO - Get Free Report) posted its earnings results on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.05), FiscalAI reports. Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%. The firm had revenue of $45.46 million for the quarter, compared to analyst estimates of $52.10 million.

Here are the key takeaways from Organogenesis' conference call:

• Third-quarter net product revenue fell 70% year over year, though it rose 6% sequentially. The company lowered its 2026 revenue outlook to $179 million–$200 million and described the market recovery as more measured than previously expected.
• Organogenesis said it gained market share, with claims data indicating its share increased more than 30% versus Q1, and reported sequential sales growth across Advanced Wound Care and Surgical & Sports Medicine. Management believes the market has bottomed, while acknowledging that low-cost inventory and ongoing customer uncertainty may continue to affect recovery.
• The company reported a $29.6 million GAAP net loss and had $26.9 million in cash and restricted cash at quarter-end, down from $94.3 million at year-end 2025. Management expects further sequential improvement in adjusted EBITDA, but positive adjusted EBITDA in Q4 is anticipated only at the high end of its outlook.
• The FDA review of Amnuvx faces a longer timeline after the agency identified 18 items requiring remediation at the Norwood facility and requested additional clinical information. The company expects remediation to finish by September 2027, estimates an $8 million total cost, and said the PDUFA target date will be extended from April 2027.

Organogenesis Price Performance

NASDAQ ORGO traded down $0.03 during trading hours on Thursday, hitting $0.84. 708,108 shares of the company were exchanged, compared to its average volume of 1,074,363. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.00. The company has a 50 day moving average of $1.28 and a two-hundred day moving average of $2.32. Organogenesis has a 52-week low of $0.73 and a 52-week high of $7.08.

Analysts Set New Price Targets

ORGO has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Organogenesis from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 19th. Weiss Ratings cut shares of Organogenesis from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, October 19th. Finally, Truist Financial lowered their price objective on shares of Organogenesis from $3.00 to $2.00 and set a "hold" rating for the company in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Reduce" and a consensus target price of $4.33.

Organogenesis Company Profile

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.